BioXcel Therapeutics, Inc. (BTAI)

Market Cap	11.93M
Revenue (ttm)	1.85M
Net Income (ttm)	-40.06M
Shares Out	6.06M
EPS (ttm)	-12.28
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	140,256
Open	2.000
Previous Close	2.000
Day's Range	1.910 - 2.057
52-Week Range	1.170 - 21.920
Beta	0.04
Analysts	Buy
Price Target	34.60 (+1,656.35%)
Earnings Date	Aug 5, 2025

About BTAI

BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving film formulation of dexmedetomidine in...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 8, 2018
• Employees: 37
• Stock Exchange: NASDAQ
• Ticker Symbol: BTAI
• Website: https://www.bioxceltherapeutics.com

Financial Performance

In 2024, BioXcel Therapeutics's revenue was $2.27 million, an increase of 64.20% compared to the previous year's $1.38 million. Losses were -$59.60 million, -66.71% less than in 2023.

Analyst Summary

According to 5 analysts, the average rating for BTAI stock is "Buy." The 12-month stock price target is $34.6, which is an increase of 1,656.35% from the latest price.

Price Target

$34.6

(1,656.35% upside)

Analyst Consensus: Buy